Robots take on tricuspid valve repair in tiny early trial

NCT ID NCT07516145

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests a robotic catheter system to replace the tricuspid valve in 10 patients with severe leakage (regurgitation) who are too high-risk for open surgery. The robot aims to improve precision and safety while reducing radiation exposure for doctors. The main goal is to see if the procedure can be done successfully without major complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Lux-Valve Plus system (transcatheter tricuspid valve replacement device) delivered via a robotic catheter
What this could lead to
If successful, this could make tricuspid valve replacement safer and more precise, reducing recovery time and radiation exposure for patients.
What could go wrong
This is a very early, small trial with only 10 participants. The robotic system is new and unproven; risks include procedural failure, bleeding, stroke, or device complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSCATHETER VALVE REPLACEMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Prince of Wales Hospital

    RECRUITING

    Shatin, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.